Navigation Links
InVitria Announces Launch of Recombinant Albumin for Diagnostics

Fort Collins, CO, April 17, 2009 / b3c newswire / - Addressing significant product safety and consistency issues in the human diagnostics market, InVitria has announced the commercial launch of two protease-free recombinant albumin products. InVitria’s Recombinant Albumin-DX and Recombinant Albumin-DX (Lipid-Free) perform better in diagnostics applications than both bovine serum albumin (BSA) and plasma-derived human serum albumin (pHSA). 
  • The advantages of Recombinant Albumin-DX include:
  • Reduce non-specific binding and improve specificity;
  • Improved consistency due to recombinant manufacturing;
  • Improved stabilization of sensitive proteins and biomarkers; and
  • Reduce occupational safety risk and regulatory burden of handling human or animal blood products.
Customer testing has shown that Recombinant Albumin-DX (Lipid-Free) increased biomarker activity to levels twice as high as the current commercial alternative. In addition, stability over time was significantly improved with Recombinant Albumin-DX (Lipid-Free). Tests have also shown the bioequivalence of the Recombinant Albumin-DX to native human serum albumin (HSA).  
“InVitria is committed to developing high performance, regulatory friendly products for the diagnostics market and our Recombinant Albumin-DX and DX Lipid-Free products deliver on this promise,” said the company’s President and CEO Scott Deeter. “Recombinant Album-DX and DX Lipid-Free provide the specificity, stability and consistency that diagnostic customers seek.”
To receive a Recombinant Albumin-DX or DX Lipid-Free product materials packet, please contact InVitria’s customer service specialists at 1-800-916-8311 or by e-mail at
ws" timex="4/17/2009 5:26:57 AM" dirsub="(bsp; About InVitria InVitria develops ...)" id="8019" index="biology" dir="InVitria Announces Launch of Recombinant Albumin for Diagnostics" dir2="InVitria Announces Launch of Recombinant Albumin for D..." keywords1=",biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters" keywords="InVitria,Announces,Launch,of,Recombinant,Albumin,for,Diagnostics" description="bsp; About InVitria InVitria develops manufactures and markets a portfolio of cell culture and diagnostic reagents. These products are used in cell culture biopharmaceutical formulation stem cell & regenerative medicine medical devices and diagnostics.   Learn more about InVitria’s products at a target _blank href" url=u&"/biology-news-1/InVitria-Announces-Launch-of-Recombinant-Albumin-for-Diagnostics-8019-2/" title="InVitria%20Announces%20Launch%20of%20Recombinant%20Albumin%20for%20Diagnostics" %> InVitria Announces Launch of Recombinant Albumin for D... (Fort Collins CO April 17 2009 / b3c news...)
InVitria Announces Launch of Recombinant Albumin for Diagnostics
Post Your Comments:
(Date:10/12/2015)... Research and Markets ( ) ... Recognition Market by Component (Hardware & Software), Product ... Industry (Travel & Immigration, Military & Defense, & ... report to their offering. ... Market worth 3627.90 Million USD by 2020 ...
(Date:10/8/2015)... LAKE CITY , 8. Oktober 2015 ... TRCK), ein global tätiges Unternehmen des Bereiches ... einem Vertrag mit der Gefängnisbehörde Virginias (Department ... dessen Rahmen elektronische Überwachungsdienste für alle Strafen ... Derek Cassell , Präsident für den ...
(Date:10/7/2015)... NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... long- term executive at American Express has been appointed ... ) ("NXT-ID" or the "Company"), a biometric authentication company ... of the Wocket® smart wallet announces Mr. Stanley ...
Breaking Biology News(10 mins):
(Date:10/12/2015)... cell surface marker detection market ... to a new report by Grand View Research, Inc. This ... of oncology diseases and other cell-associated disorders. --> ... USD 6.49 billion by 2022, according to a new report ... be attributed to rise in incidence of oncology diseases and ...
(Date:10/12/2015)... 2015  Patara Pharma, a clinical-stage biotechnology company ... and conditions, today announced the closing of a ... with the close of its sale of preferred ... Security Agreement with Silicon Valley Bank whereby the ... will use the funds from the financing to ...
(Date:10/12/2015)... 12, 2015 VolitionRx Limited (NYSE MKT: ... study of its NuQ ® blood-based test for early ... of Clinical Epigenetics , the official journal of the ... with Lund University, Sweden ... PhD, Professor of Surgery and Vice-Dean, Faculty of Medicine. ...
(Date:10/12/2015)... ... October 12, 2015 , ... LifeTrak , a leader in ... Zoom, the world’s first amphibious fitness tracker that seeks to meet the needs of ... accurate heart rate monitoring both in water and on land, making it ...
Breaking Biology Technology: